Last reviewed · How we verify
US Remicade — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
US Remicade (US Remicade) — Samsung Bioepis Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| US Remicade TARGET | US Remicade | Samsung Bioepis Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- US Remicade CI watch — RSS
- US Remicade CI watch — Atom
- US Remicade CI watch — JSON
- US Remicade alone — RSS
Cite this brief
Drug Landscape (2026). US Remicade — Competitive Intelligence Brief. https://druglandscape.com/ci/us-remicade. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab